<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571662</url>
  </required_header>
  <id_info>
    <org_study_id>389-00</org_study_id>
    <secondary_id>IRB389-00</secondary_id>
    <nct_id>NCT00571662</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant</brief_title>
  <official_title>Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a continuation of a pilot study which is now regarded as a phase II trial with a plan
      to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with
      hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive
      regimen with pentostatin and low-dose total body irradiation (TBI) followed by allogeneic
      peripheral blood stem cell transplantation (alloPSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study which began with a plan to enroll 50 patients (20 related and 30
      unrelated donor transplants) with hematological malignancy assessing the safety and efficacy
      of a minimally myelosuppressive regimen with Pentostatin and low-dose total body irradiation
      (TBI) followed by allogeneic peripheral blood stem cell transplantation (alloPSCT). Patients
      with persistent or progressive malignancy after transplantation will be treated with GM-CSF
      (cytokine therapy) to assess its toxicity and potential therapeutic efficacy. Patients with
      persistent or progressive disease who fail or do not qualify for the cytokine therapy portion
      of the study will become candidates for donor leukocyte infusions.

      The purpose of this protocol remains a pilot study which is now regarded as a phase II trial
      with a plan to enroll 40 ADDITIONAL patients (20 related and 20 unrelated donor transplants)
      with hematological malignancy assessing the safety and efficacy of a modified version of the
      original preparative regimen of Pentostatin and low-dose total body irradiation (TBI)
      followed by allogeneic peripheral blood stem cell transplantation (alloPSCT). Patients who
      fail will become candidates for donor-leukocyte infusion (DLI).

      Primary Objectives

        1. To determine the safety of treating hematological malignancies by establishing donor
           hematopoietic chimerism using pentostatin and low-dose total body irradiation followed
           by allogeneic peripheral blood stem cell transplantation.

        2. To determine the immunomodulatory effects of pentostatin as part of the conditioning
           regimen for allogeneic peripheral blood stem cell transplantation.

      Secondary Objectives

        1. To determine the incidence of infections after using a minimally myelosuppressive
           conditioning regimen.

        2. To determine the kinetics of hematological and immunological reconstitution after
           allotransplantation with a minimally myelosuppressive conditioning regimen.

        3. To determine the incidence of chronic GVHD after using allogeneic peripheral blood stem
           cell transplantation with a minimally myelosuppressive preparative regimen.

        4. To evaluate the role of the preparative regimen and donor source (related versus
           unrelated) on inflammatory cytokine profiles.

        5. To evaluate blood and where possible, biopsy specimens for a recently identified nuclear
           protein (molecular weight 44/46) in mononuclear cells obtained from study subjects.

      Interventions, evaluation, and follow up will include:

      Pentostatin 4 mg/m^2/d intravenously once a day x 3 days will be administered with 1000 cc NS
      hydration before and after pentostatin ten days prior to stem cell infusion (days -10, -9,
      and -8). Total-body irradiation (TBI): TBI 2.0 Gy will be given on day -1. Antiemetics will
      be given as needed. Patients will receive one liter normal saline over 2 hours pre TBI. A
      bone marrow biopsy and aspiration with cytogenetics and flow cytometry will be performed on
      Day +28, Day +70 and 6, 12, 18 and 24 months following the transplant to monitor hematologic
      recovery. DNA fingerprinting will also be conducted at the same time at 3, 4, 5, 6, 12, 18,
      and 24 months to determine chimerism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Chimerism: Full Donor Chimerism Defined as &gt;95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting</measure>
    <time_frame>days +28 and +70</time_frame>
    <description>the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute and Chronic Graft-versus-host Disease</measure>
    <time_frame>twice weekly until day 100 up to 1 year post transplant</time_frame>
    <description>Incidence of acute and chronic graft-versus-host disease.Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to Therapy</measure>
    <time_frame>every 6 mo. up to 2 years</time_frame>
    <description>event-free and overall survival at 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <condition>Hodgkins Disease</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <description>4 mg/m^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)</description>
    <arm_group_label>Cohort I</arm_group_label>
    <other_name>Nipent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-body irradiation (TBI)</intervention_name>
    <description>TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.</description>
    <arm_group_label>Cohort I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A (CsA)</intervention_name>
    <description>CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD</description>
    <arm_group_label>Cohort I</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil (MMF)</intervention_name>
    <description>MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.</description>
    <arm_group_label>Cohort I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 mcg/kg/day subcutaneously for at least 4 consecutive days.</description>
    <arm_group_label>Cohort I</arm_group_label>
    <other_name>Leukine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 19-75 years

          1. Patients who relapse after autologous stem cell transplantation.

          2. Patients who are candidates for an autologous or conventional allogeneic stem cell
             transplantation from a disease standpoint but who do not qualify functionally (from
             the point of view of organ function, or performance status) for a myeloablative
             protocol.

          3. Any patient, where in the opinion of the primary treating oncologist, nonmyleoablative
             therapy would be the treatment option in the best patients interest providing the
             patient fits all other eligibility criteria for this protocol.

        Identification of a matched related or unrelated stem cell donor

        Diseases:

        Acute myelogenous leukemia first complete remission with high-risk cytogenetics&gt;second
        complete remission minimal residual disease (&lt;10% blasts*). Acute lymphocytic leukemia
        first complete remission with high-risk cytogenetics &gt;second complete remission minimal
        residual disease (&lt;10% blasts*). Chronic myelogenous leukemia first chronic phase,
        accelerated phase (&lt;10% blasts*)blast phase with minimal residual disease (&lt;10%
        blasts*)second chronic phase. Chronic lymphocytic leukemia recurrence after the front line
        regimen (related donor transplant), chemorefractory disease (unrelated donor
        transplant),T-CLL in partial remission or any minimal residual disease. Myelodysplastic
        syndromes refractory anemia with or without ringed sideroblasts,RAEB, RAEB-T, and CMML (&lt;
        than 10% blasts*). *both in peripheral blood and bone marrow

        Multiple myeloma - after receiving at least one regimen of prior chemotherapy

        Non-Hodgkin's Lymphomas:

        Small Lympho(plasma)cytic Lymphoma (B-SLL, B-LPL): recurrence after a front line regimen
        (related donor transplant), or chemorefractory disease (related or unrelated donor
        transplant). Follicular Low-Grade Lymphoma, Marginal Zone Lymphomas (splenic, nodal, or
        extranodal/MALT type): chemorefractory disease or &gt; 2 prior regimens. Mantle Cell Lymphoma:
        first complete or partial remission, refractory disease, or failed prior ASCT. Diffuse
        Large B-cell Lymphoma, Follicular Large cell Lymphoma, Peripheral T-cell Lymphoma,
        Anaplastic Large Cell Lymphoma: refractory disease, or failed prior ASCT. Burkitt or Acute
        Lymphoblastic Lymphomas: high-risk disease in remission, chemosensitive persistent or
        recurrent disease. Cutaneous T-cell Lymphomas: (Mycosis Fungoides, Sezary Syndrome):
        chemorefractory disease of &gt; 2 prior regimens

        Hodgkins Disease: refractory or persistent disease and not candidate for ASCT, or failed
        prior ASCT.

        Peripheral T-cell Lymphoma

        Exclusion Criteria:

          -  Age &gt; 75 years and &lt; 19 years

          -  progressive disease within 8 weeks of prior therapy or within 12 weeks after prior
             autologous stem cell transplantation

          -  Active CNS malignancy (patients with known positive CSF cytology or parenchymal
             lesions visible by CT or MRI)

          -  Fertile men or women unwilling to use appropriate contraceptive techniques during and
             for 12 months following treatment

          -  Females who are pregnant

          -  Patients who are HIV seropositive

          -  Active uncontrolled infection or immediate life-threatening condition at the time of
             enrollment

          -  Significant Organ dysfunction:

               1. Calculated Creatinine Clearance &lt;55ml/min

               2. cardiac ejection fraction &lt;40%, NYHA class II or greater cardiac disease.

               3. DLCO &lt; 40% , FEV1/FVC ratio &lt;50% predicted, or receiving supplementary continuous
                  oxygen

               4. total bilirubin &gt; 2x upper limit of normal (unless due to Gilberts disease or
                  malignancy), ALT and AST 4x the upper limit of normal

          -  Karnofsky score &lt;60%

          -  Patients with uncontrolled medical illnesses (e.g., uncontrolled systemic
             hypertension, diabetes)

        Donor Inclusion Criteria:

          -  HLA genotypically matched relative

          -  siblings or first-degree relatives matched at HLA-A, B, or DR loci (6 antigen match)
             are acceptable donors

          -  HLA matched unrelated volunteer donor

          -  unrelated donor matched at HLA-A, B, or DR loci (6 antigen match) are acceptable
             donors

          -  One antigen mismatch related or unrelated donor will also be acceptable, molecular
             typing needs to be used at each H LA-A, B, or DR loci in case of mismatched unrelated
             donor.

        Donor Exclusion Criteria:

          -  Identical twin

          -  Pregnancy

          -  HIV positive

          -  Serious Allergy to G-CSF

          -  Current serious systemic illness

          -  Failure to meet the UNMC or NMDP criteria for donors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Bociek, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Section of Oncology/Hematology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <results_first_submitted>October 19, 2010</results_first_submitted>
  <results_first_submitted_qc>October 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2010</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>R. Gregory Bociek, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between November 2001 and February 2007 sixty eight patients were treated on this protocol and have been included in the analysis</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I</title>
          <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>psychiatric instability</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I</title>
          <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="21" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Chimerism: Full Donor Chimerism Defined as &gt;95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting</title>
        <description>the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.</description>
        <time_frame>days +28 and +70</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I</title>
            <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Chimerism: Full Donor Chimerism Defined as &gt;95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting</title>
          <description>the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.</description>
          <units>percent of participants</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="40" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="45" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute and Chronic Graft-versus-host Disease</title>
        <description>Incidence of acute and chronic graft-versus-host disease.Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant.</description>
        <time_frame>twice weekly until day 100 up to 1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I</title>
            <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute and Chronic Graft-versus-host Disease</title>
          <description>Incidence of acute and chronic graft-versus-host disease.Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant.</description>
          <units>Percent of Particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responses to Therapy</title>
        <description>event-free and overall survival at 12 months</description>
        <time_frame>every 6 mo. up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I</title>
            <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Responses to Therapy</title>
          <description>event-free and overall survival at 12 months</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Event free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort I</title>
          <description>Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased WBC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>decreased ANC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>decreased hgb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>decreased platelets</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>decreased leukocyte</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased LDH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>reddened catheter site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>azotemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>atubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R. Gregory Bociek, MD</name_or_title>
      <organization>University of Nebraska Medical Center Division of Oncology/Hematology</organization>
      <phone>402-559-5388</phone>
      <email>rgbociek@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

